a. baumannii

Blasticidin S HCl is a natural product and an inhibitor of protein synthesis. Blasticidin S HCl is a broad-spectrum antibiotic that can inhibit the cell growth of prokaryotes, fungi, plants and mammalian cells.

Tigecycline (GAR-936) is a broad-spectrum glycylcycline antibiotic derived from tetracycline that binds to the 30S ribosomal subunit, disrupting the binding of aminoacyl-tRNA to the mRNA-ribosome complex.

Cyclo-L-Trp-L-Trp is a broad-spectrum antifungal. It also induces a high degree of acetylation of histones.

MLEB-22043 is a synthetic siderophore-monocyclic β-lactam conjugate which enters bacteria through TonB-dependent transport proteins utilizing its siderophore component, subsequently exerting antibacterial activity via its β-lactam portion. This compound acts as a broad-spectrum antibiotic, exhibiting significant inhibitory activity against pathogens such as Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii, and Pseudomonas aeruginosa.

Debio-1452-NH3 is a novel and potent FabI antibody—enoyl-acyl carrier protein reductase inhibitor that demonstrates excellent efficacy in reducing bacterial load in mice. It effectively treats lethal infections caused by clinically isolated strains of Pseudomonas aeruginosa (Acinetobacter baumannii), Klebsiella pneumoniae, and Escherichia coli (E. coli).

YFJ-36 is an antibiotic that demonstrates superior and broad-spectrum antibacterial activity in vitro compared to cefiderocol, particularly against A. baumannii and K. pneumoniae. In a systemic infection model in mice, YFJ-36 exhibits strong in vivo efficacy. Additionally, the compound shows enhanced physicochemical stability in liquid media with a pH of 6-8 and is noteworthy for its potential to reduce allergy risk due to its quaternary ammonium bond.

(E)-2,6-Di-tert-butyl-4-(4-(diethylamino)styryl)pyrylium TFA (Compound 4a) functions as a Gram-negative outer membrane permeabilizer by targeting Met47 in LptA to disrupt LptA/LptC interactions, exhibiting synergistic antibacterial activity. This compound, when in the form of (trifluoromethanesulfonate), enhances the efficacy of pol B against both wild-type and multi-drug resistant A. baumannii and E. coli strains. Additionally, (E)-2,6-Di-tert-butyl-4-(4-(diethylamino)styryl)pyrylium (trifluoromethanesulfonate) serves as an adjuvant for antibiotics combating multi-drug resistant Gram-negative bacteria.

FtsZ-IN-12 (Compound 16e) is an inhibitor of filamentous temperature-sensitive mutant Z (FtsZ) that promotes the polymerization of the FtsZ protein and suppresses its GTPase activity, thus disrupting the bacterial cell division process. This compound exhibits broad-spectrum antibacterial activity, effectively inhibiting B. subtilis ATCC 9372, B. pumilus CMCC 63202, S. aureus ATCC 25923, E. coli BW25113, and A. baumannii ATCC 19606 with MIC values ranging from 0.062-1 µg/mL. Additionally, FtsZ-IN-12 can inhibit biofilm formation and eliminate mature biofilms. It possesses bactericidal properties and shows no hemolytic toxicity to mammalian red blood cells at a dosage of 15 mg/kg.

Antibacterialagent 274 (Compound 18b) is an antibacterial agent that targets bacterial cell membranes, exhibiting a minimum inhibitory concentration (MIC) of 8 μg/mL against Acinetobacter baumannii ATCC 17978. It functions by disrupting membrane integrity, causing intracellular accumulation of ROS, which leads to DNA and protein leakage, thereby exerting its antibacterial effects. Antibacterialagent 274 is applicable in research on infections caused by Gram-negative bacteria.

Zosurabalpin TFA is a macrocyclic peptide antibiotic that specifically targets Acinetobacter baumannii (A. baumannii) by inhibiting lipopolysaccharide transport.

IITR08367 is a potent inhibitor of the efflux pump Acinetobacter baumannii Fosfomycin Efflux pump (AbaF), designed to enhance the antibacterial activity of Fosfomycin against Acinetobacter baumannii. It operates by disrupting the Fosfomycin/H+ antiport activity.

Antibacterialagent 285 (Compound 3) is a cephalosporin antibiotic. It exhibits significant antibacterial activity against Gram-negative bacteria, with minimum inhibitory concentrations (MIC) of 0.125-0.5 μg/mL for carbapenem-resistant Acinetobacter baumannii (CRAB), 0.125-0.5 μg/mL for Klebsiella pneumoniae (CRE), and 0.125-2 μg/mL for Pseudomonas aeruginosa (CRPA). Antibacterialagent 285 can be utilized in bacterial infection research, including studies on complicated urinary tract infections (cUTI) and kidney infections.

CYP1A1-IN-1 (Compound 47) is a small molecule inhibitor of cytochrome P450 1A1 (CYP1A1). It reduces the bacterial load of methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii by enhancing macrophage phagocytosis. CYP1A1-IN-1 shows potential for research in sepsis caused by multi-drug resistant (MDR) bacteria.

ANT3310 is a broad-spectrum covalent inhibitor of serine β-lactamase (Serine β-Lactamase) with an IC50 range of 1 nM to 175 nM against various serine β-lactamases. ANT3310 enhances the efficacy of β-lactam antibiotics against carbapenem-resistant Enterobacteriaceae (CRE) and carbapenem-resistant Acinetobacter baumannii (CRAB). It is applicable for studies related to bacterial infections.

Antibacterialagent 294 is an antimicrobial compound effective against carbapenem-resistant Acinetobacter baumannii (CRAB), with a minimum inhibitory concentration (MIC) of 0.5 μg/mL. It is utilized in research related to infections.

Moxifloxacinprodrug-1 TFA (Compound 1e) is a prodrug of Moxifloxacin and functions as an antibacterial agent. It exhibits potent activity against Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa, comparable to Moxifloxacin. Additionally, Moxifloxacin prodrug-1 TFA is capable of inhibiting Mycobacterium tuberculosis.

Tigecycline hydrochloride is a first-in-class, broad-spectrum antibiotic. It also has activity against antibiotic-resistant organisms.

Tigecycline mesylate is a first-in-class, broad-spectrum antibiotic. It also has activity against antibiotic-resistant organisms.

DS-8587 is a DNA topoisomerase inhibitor. DS-8587 exhibits potent antibacterial activity against quinolone-resistant A. baumannii isolates that harbor mutations in quinolone resistance-determining regions. DS-8587 significantly reduces the number of viabl

DS86760016 is a highly effective inhibitor of leucyl-tRNA synthetase (LeuRS), demonstrating potent activity against multidrug-resistant (MDR) Gram-negative bacteria including Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Notably, DS86760016 effectively inhibits LeuRS enzymes derived from Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii, exhibiting IC50 values of 0.38 μM, 0.62 μM, and 0.16 μM, respectively.

SPR206 acetate is a polymyxin analog that exhibits antibiotic activity against Gram-negative pathogens, including multidrug-resistant (MDR) variants. By interacting with the outer membrane of the bacterium, SPR206 acetate efficiently combats bacterial infections, displaying significant efficacy with minimum inhibitory concentration (MIC) values of 0.125 mg/L against [Pseudomonas aeruginosa Pa14] and [Acinetobacter baumannii NCTC13301].

APO-6619 is an iron chelator which was shown to inhibit growth of the following bacterial strains: Acinetobacter baumannii, Pseudomonas aeruginosa, Staphylococcus aureus, Klebsiella pneumoniae, and Escherichia coli. APO-6619 may be useful as a non-traditional treatment of bacterial infections.

TP-6076 is a fluorocycline antibiotic, inhibiting bacterial protein synthesis, exhibiting great antimicrobial activity against carbapenem-resistant A. baumannii.

Benastatin B is a polyketide synthase-derived benastatin that has been found in Streptomyces and has diverse biological activities. It inhibits glutathione S-transferase (GST; Ki = 3.7 µM for the rat liver enzyme).2 Benastatin B also inhibits the transglycosylase activity of A. baumannii, C. difficile, E. coli, and S. aureus recombinant penicillin-binding proteins (PBPs; IC50s = 16, 53.3, 30.7, and 31.6 µM, respectively).3 It is active against several bacteria, including methicillin-resistant S. aureus (MRSA; MIC = 3.12 µg/ml).